sales@fnfresearch.comTel: +91 96043 17127 | USA: 1 (347) 690-0211

Search Market Research Report

Home / Category / Healthcare / Fabry Disease Treatment

Fabry Disease Treatment Market by Drugs (Agalsidase Beta, Migalastat, and Pipeline Drugs), By Treatment (Enzyme Replacement Therapy (ERT), Chaperone Treatment, Substrate Reduction Therapy (SRT), and Others), By Route of Administration (Oral, and Intravenous) and By Region: Global Industry Perspective, Comprehensive Analysis, and Forecast, 2020 – 2026

  • Publish On: Apr-2021
  • Total Pages: 195
  • Report Code: FAF-1432
  • Base Year: 2020
  • Format:

Industry Insights

[195+ Pages Report] As per the market research report published by Facts and Factors, the global Fabry disease treatment market was valued at approximately USD 1.77 billion in 2019 and is expected to generate revenue of around USD 3.78 billion by end of 2026, growing at a CAGR of around 9.83% between 2020 and 2026.

Global Fabry Disease Treatment Market: Overview       

Fabry disease is an X-linked lysosomal storage condition. The deficiency of the alpha-galactosidase enzyme in a patient causes progressive organ dysfunction. The development of Fabry diseases is primarily caused by an abnormal accumulation of a particular fatty matter known as globotriaosylceramide. The skin, heart, eyes, brain, kidneys, central nervous system, and gastrointestinal system are all affected by this irregular accumulation.

Global Fabry Disease Treatment Market: Growth Factors

The treatment's main goal is to reduce and alleviate the patients' crippling discomfort while also preventing disease progression. Fabry's disease cannot be cured, but the harm it causes can be reduced with proper treatment. In the year 2003, the FDA approved the intravenous administration of Agalsidase as an enzyme replacement therapy (ERT) for the treatment of Fabry's disease. Before that, patients were given carbamazepine and diphenylhydantoin to relieve pain, and their estimated lifespan was between 40 and 50 years. The use of new treatments such as substrate replacement therapy and chaperone treatment has risen rapidly in recent years. However, enzyme replacement therapy has long been the most popular treatment, with a large market share that is expected to sustain during the forecast period. The market is growing as the number of patients suffering from Fabry disease is increasing. Aside from that, broad R&D activities and the potential approval and launches of promising pipeline products such as substrate decline treatments and compound replacement treatments are expected to boost the industry's growth over the forecast period. In addition, the market is expected to expand due to the legalization of oral chaperone therapy in developing countries and the advancement of gene therapy. Additionally, due to patent expirations, the proliferation of biosimilars is expected to increase during the forecast era. Patients with Fabry disease often experience strokes, excruciating pain, an early heart condition, impaired kidney function, which may contribute to kidney failure, and debilitating gastrointestinal symptoms. Since there is no cure for Fabry disease, care focuses on managing complications associated with disease progression and providing symptomatic relief. Various patients are often misdiagnosed due to mild symptoms. The global Fabry disease market is expected to expand at a significant pace in the coming years as a result of these factors.

Global Fabry Disease Treatment Market: Segmentation

The global Fabry disease treatment Market is segregated into drugs, route of administration, treatment, and regions.  The drug category is segmented into migalastat, agalsidase beta, and pipeline drugs. The pipeline drugs are expected to hold highest market share in 2019. Based on treatment, the market has been categorized into substrate reduction therapy, chaperone treatment, enzyme replacement therapy, and others. Both Shire's Replagal, and Sanofi's Fabrazyme have received European approval, only Fabrazyme has received approval in the United States. Current clinical trials are focusing on improving the safety and efficacy profile of ERTs, as well as the development of innovative oral therapies that can replace intravenous infusions. The segment's dominance is supported by strong sales of Fabrazyme and Replagal, as well as the possible acceptance of successful pipeline candidates. However, the introduction of new, more effective treatment methods, such as gene therapy, is critical for a significant improvement in patient benefits. In terms of route of administration, the market has been segregated into oral, and intravenous.

Global Fabry Disease Treatment Market: Regional Analysis

Due to various expanding human service use and developing infrastructure, Asia Pacific offers major growth opportunities for pharmaceutical companies. Because of the large populations in emerging countries, the region is expected to grow the fastest in the coming years, followed by Latin America. In 2018, North America surpassed Europe as the most important regional market. Increased availability of innovative therapies, improved social insurance offices, and favorable reimbursement terms are all playing important roles in the region's business growth. Inclusion of expensive medications like Fabrazyme by health insurance plans, as well as favorable regulatory medicinal services arrangements, are also encouraging pharmaceutical companies to increase R&D activity in the field of rare diseases.

Global Fabry Disease Treatment Market: Competitive Players

Some main participants of the global Fabry disease treatment market are ISU Abxis Co Ltd., Greenovation Biotech GmbH, Amicus Therapeutics Inc., Avrobio Inc., Shire Plc., Sanofi S.A.,  Moderna Therapeutics Inc., JCR Pharmaceuticals, Protalix Biotherapeutics Inc., and Idorsia Pharmaceuticals Ltd., amongst others.

Fabry Disease Treatment Market: Regional Segment Analysis

  • North America
    • U.S.
    • Canada
  • Europe
    • UK
    • France
    • Germany
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • GCC Countries
    • South Africa
    • Rest of MEA

KEY REPORT POINTERS & HIGHLIGHTS:

  • Statistically Validated Analysis of Historical, Current, and Projected Industry Trends with Authenticated Market Sizes Information and Data in terms of Value and Volume, wherever applicable
  • Direct and Indirect Factors that Impacted the Industry as well Projected Rationales expected to affect the industry going forward
  • Micro, Meso, Macro, and In-Depth Analysis of Technically relevant and Commercially viable  Segments and Sub-segments of the Market
  • Historical and Projected Company / Vendor / OEM / Supplier Market Shares, Competitive Landscape, and Player Positioning Data
  • Historical and Current Demand (Consumption) and Supply (Production) Scenarios as well as Projected Supply-Demand Scenario Analysis
  • Detailed List of Key Buyers and End-Users (Consumers) analyzed as per Regions and Applications
  • Value Chain and Supply Chain Analysis along with Horizontal and Vertical Integration Scenarios
  • Manufacturing and Production Cost Structure Analysis including Labor Cost, Raw Material Expenses, and Other Manufacturing Expenses, wherever relevant
  • Overview of Key Marketing Strategies and Key Sales Channels Adopted in the Market
  • Market Attractiveness Analysis and Key Investment Opportunity Analysis in the Market going forward
  • Technological Roadmap, Patents Analysis, Potential Substitutes, and Technical Analysis
  • The professionally substantiated market research report study is calculated, constructed, and assembled by implementing a Robust Research Methodology. The Triangular Process comprises a buoyant mix of Exhaustive Primary Research (focused interviews, questionnaires, and ad-hoc surveys) and Extended Secondary Research (paid external databases, proprietary in-house database, and publically-available validated sources), where it is finally triangulated and validated through in-house industry experts, industry leaders, and independent consultants through a tri-level quality check practice.

Table of Content

  1. Chapter 1 Executive Summary
    1. 1.1. Introduction of Fabry Disease Treatment
    2. 1.2. Global Fabry Disease Treatment Market, 2019 & 2026 (USD Million)
    3. 1.3. Global Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 1.4. Global Fabry Disease Treatment Market Absolute Revenue Opportunity, 2016 – 2026 (USD Million)
    5. 1.5. Global Fabry Disease Treatment Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)
  2. Chapter 2 Fabry Disease Treatment Market – Drugs Analysis
    1. 2.1. Global Fabry Disease Treatment Market – Drugs Overview
    2. 2.2. Global Fabry Disease Treatment Market Share, by Drugs, 2019 & 2026 (USD Million)
    3. 2.3. Agalsidase Beta
      1. 2.3.1. Global Agalsidase Beta Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 2.4. Migalastat
      1. 2.4.1. Global Migalastat Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    5. 2.5. Pipeline Drugs
      1. 2.5.1. Global Pipeline Drugs Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
  3. Chapter 3 Fabry Disease Treatment Market – Treatment Analysis
    1. 3.1. Global Fabry Disease Treatment Market – Treatment Overview
    2. 3.2. Global Fabry Disease Treatment Market Share, by Treatment, 2019 & 2026 (USD Million)
    3. 3.3. Enzyme Replacement Therapy (ERT)
      1. 3.3.1. Global Enzyme Replacement Therapy (ERT) Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 3.4. Chaperone Treatment
      1. 3.4.1. Global Chaperone Treatment Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    5. 3.5. Substrate Reduction Therapy (SRT)
      1. 3.5.1. Global Substrate Reduction Therapy (SRT) Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    6. 3.6. Others
      1. 3.6.1. Global Others Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
  4. Chapter 4 Fabry Disease Treatment Market – Route of Administration Analysis
    1. 4.1. Global Fabry Disease Treatment Market – Route of Administration Overview
    2. 4.2. Global Fabry Disease Treatment Market Share, by Route of Administration, 2019 & 2026 (USD Million)
    3. 4.3. Oral
      1. 4.3.1. Global Oral Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 4.4. Intravenous
      1. 4.4.1. Global Intravenous Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
  5. Chapter 5 Fabry Disease Treatment Market – Regional Analysis
    1. 5.1. Global Fabry Disease Treatment Market Regional Overview
    2. 5.2. Global Fabry Disease Treatment Market Share, by Region, 2019 & 2026 (USD Million)
    3. 5.3. North America
      1. 5.3.1. North America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.3.1.1. North America Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.3.2. North America Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.3.2.1. North America Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.3.3. North America Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.3.3.1. North America Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.3.4. North America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.3.4.1. North America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.3.5. U.S.
        1. 5.3.5.1. U.S. Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.3.6. Canada
        1. 5.3.6.1. Canada Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    4. 5.4. Europe
      1. 5.4.1. Europe Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.4.1.1. Europe Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.4.2. Europe Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.4.2.1. Europe Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.4.3. Europe Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.4.3.1. Europe Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.4.4. Europe Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.4.4.1. Europe Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.4.5. Germany
        1. 5.4.5.1. Germany Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.4.6. France
        1. 5.4.6.1. France Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      7. 5.4.7. U.K.
        1. 5.4.7.1. U.K. Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      8. 5.4.8. Italy
        1. 5.4.8.1. Italy Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      9. 5.4.9. Spain
        1. 5.4.9.1. Spain Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      10. 5.4.10. Rest of Europe
        1. 5.4.10.1. Rest of Europe Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    5. 5.5. Asia Pacific
      1. 5.5.1. Asia Pacific Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.5.1.1. Asia Pacific Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.5.2. Asia Pacific Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.5.2.1. Asia Pacific Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.5.3. Asia Pacific Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.5.3.1. Asia Pacific Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.5.4. Asia Pacific Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.5.4.1. Asia Pacific Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.5.5. China
        1. 5.5.5.1. China Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.5.6. Japan
        1. 5.5.6.1. Japan Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      7. 5.5.7. India
        1. 5.5.7.1. India Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      8. 5.5.8. South Korea
        1. 5.5.8.1. South Korea Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      9. 5.5.9. South-East Asia
        1. 5.5.9.1. South-East Asia Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      10. 5.5.10. Rest of Asia Pacific
        1. 5.5.10.1. Rest of Asia Pacific Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    6. 5.6. Latin America
      1. 5.6.1. Latin America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.6.1.1. Latin America Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.6.2. Latin America Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.6.2.1. Latin America Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.6.3. Latin America Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.6.3.1. Latin America Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.6.4. Latin America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.6.4.1. Latin America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.6.5. Brazil
        1. 5.6.5.1. Brazil Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.6.6. Mexico
        1. 5.6.6.1. Mexico Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      7. 5.6.7. Rest of Latin America
        1. 5.6.7.1. Rest of Latin America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
    7. 5.7. The Middle-East and Africa
      1. 5.7.1. The Middle-East and Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
        1. 5.7.1.1. The Middle-East and Africa Fabry Disease Treatment Market, by Country, 2016 - 2026 (USD Million)
      2. 5.7.2. The Middle-East and Africa Fabry Disease Treatment Market, by Drugs, 2016 – 2026
        1. 5.7.2.1. The Middle-East and Africa Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      3. 5.7.3. The Middle-East and Africa Fabry Disease Treatment Market, by Treatment, 2016 – 2026
        1. 5.7.3.1. The Middle-East and Africa Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      4. 5.7.4. The Middle-East and Africa Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026
        1. 5.7.4.1. The Middle-East and Africa Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      5. 5.7.5. GCC Countries
        1. 5.7.5.1. GCC Countries Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      6. 5.7.6. South Africa
        1. 5.7.6.1. South Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      7. 5.7.7. Rest of Middle-East Africa
        1. 5.7.7.1. Rest of Middle-East Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
  6. Chapter 6 Fabry Disease Treatment Market – Competitive Landscape
    1. 6.1. Competitor Market Share – Revenue
    2. 6.2. Market Concentration Rate Analysis, Top 3 and Top 5 Players
    3. 6.3. Strategic Developments
      1. 6.3.1. Acquisitions and Mergers
      2. 6.3.2. New Products
      3. 6.3.3. Research & Development Activities
  7. Chapter 7 Company Profiles
    1. 7.1. Sanofi S.A.
      1. 7.1.1. Company Overview
      2. 7.1.2. Product/Service Portfolio
      3. 7.1.3. Sanofi S.A. Sales, Revenue, and Gross Margin
      4. 7.1.4. Sanofi S.A. Revenue and Growth Rate
      5. 7.1.5. Sanofi S.A. Market Share
      6. 7.1.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    2. 7.2. Amicus Therapeutics Inc.
      1. 7.2.1. Company Overview
      2. 7.2.2. Product/Service Portfolio
      3. 7.2.3. Amicus Therapeutics Inc. Sales, Revenue, and Gross Margin
      4. 7.2.4. Amicus Therapeutics Inc. Revenue and Growth Rate
      5. 7.2.5. Amicus Therapeutics Inc. Market Share
      6. 7.2.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    3. 7.3. Avrobio Inc.
      1. 7.3.1. Company Overview
      2. 7.3.2. Product/Service Portfolio
      3. 7.3.3. Avrobio Inc. Sales, Revenue, and Gross Margin
      4. 7.3.4. Avrobio Inc. Revenue and Growth Rate
      5. 7.3.5. Avrobio Inc. Market Share
      6. 7.3.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    4. 7.4. Shire Plc.
      1. 7.4.1. Company Overview
      2. 7.4.2. Product/Service Portfolio
      3. 7.4.3. Shire Plc. Sales, Revenue, and Gross Margin
      4. 7.4.4. Shire Plc. Revenue and Growth Rate
      5. 7.4.5. Shire Plc. Market Share
      6. 7.4.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    5. 7.5. Idorsia Pharmaceuticals Ltd.
      1. 7.5.1. Company Overview
      2. 7.5.2. Product/Service Portfolio
      3. 7.5.3. Idorsia Pharmaceuticals Ltd. Sales, Revenue, and Gross Margin
      4. 7.5.4. Idorsia Pharmaceuticals Ltd. Revenue and Growth Rate
      5. 7.5.5. Idorsia Pharmaceuticals Ltd. Market Share
      6. 7.5.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    6. 7.6. Greenovation Biotech GmbH
      1. 7.6.1. Company Overview
      2. 7.6.2. Product/Service Portfolio
      3. 7.6.3. Greenovation Biotech GmbH Sales, Revenue, and Gross Margin
      4. 7.6.4. Greenovation Biotech GmbH Revenue and Growth Rate
      5. 7.6.5. Greenovation Biotech GmbH Market Share
      6. 7.6.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    7. 7.7. ISU Abxis Co Ltd.
      1. 7.7.1. Company Overview
      2. 7.7.2. Product/Service Portfolio
      3. 7.7.3. ISU Abxis Co Ltd. Sales, Revenue, and Gross Margin
      4. 7.7.4. ISU Abxis Co Ltd. Revenue and Growth Rate
      5. 7.7.5. ISU Abxis Co Ltd. Market Share
      6. 7.7.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    8. 7.8. Moderna Therapeutics Inc.
      1. 7.8.1. Company Overview
      2. 7.8.2. Product/Service Portfolio
      3. 7.8.3. Moderna Therapeutics Inc. Sales, Revenue, and Gross Margin
      4. 7.8.4. Moderna Therapeutics Inc. Revenue and Growth Rate
      5. 7.8.5. Moderna Therapeutics Inc. Market Share
      6. 7.8.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    9. 7.9. JCR Pharmaceuticals Co Ltd
      1. 7.9.1. Company Overview
      2. 7.9.2. Product/Service Portfolio
      3. 7.9.3. JCR Pharmaceuticals Co Ltd Sales, Revenue, and Gross Margin
      4. 7.9.4. JCR Pharmaceuticals Co Ltd Revenue and Growth Rate
      5. 7.9.5. JCR Pharmaceuticals Co Ltd Market Share
      6. 7.9.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
    10. 7.10. Protalix Biotherapeutics Inc.
      1. 7.10.1. Company Overview
      2. 7.10.2. Product/Service Portfolio
      3. 7.10.3. Protalix Biotherapeutics Inc. Sales, Revenue, and Gross Margin
      4. 7.10.4. Protalix Biotherapeutics Inc. Revenue and Growth Rate
      5. 7.10.5. Protalix Biotherapeutics Inc. Market Share
      6. 7.10.6. Recent Initiatives, Funding/VC Activities, and Technological Innovations
  8. Chapter 8 Fabry Disease Treatment — Industry Analysis
    1. 8.1. Introduction and Taxonomy
    2. 8.2. Fabry Disease Treatment Market – Key Trends
      1. 8.2.1. Market Drivers
      2. 8.2.2. Market Restraints
      3. 8.2.3. Market Opportunities
    3. 8.3. Value Chain Analysis
    4. 8.4. Key Mandates and Regulations
    5. 8.5. Technology Roadmap and Timeline
    6. 8.6. Fabry Disease Treatment Market – Attractiveness Analysis
      1. 8.6.1. By Drugs
      2. 8.6.2. By Treatment
      3. 8.6.3. By Route of Administration
      4. 8.6.4. By Region
  9. Chapter 9 Industrial Chain, Sourcing Strategy, and Downstream Buyers
    1. 9.1. Fabry Disease Treatment Industrial Chain Analysis
    2. 9.2. Downstream Buyers
    3. 9.3. Distributors/Traders List
  10. Chapter 10 Marketing Strategy Analysis
    1. 10.1. Marketing Channel
    2. 10.2. Direct Marketing
    3. 10.3. Indirect Marketing
    4. 10.4. Marketing Channel Development Trends
    5. 10.5. Economic/Political Environmental Change
  11. Chapter 11 Report Conclusion & Key Insights
    1. 11.1. Key Insights from Primary Interviews & Surveys Respondents
    2. 11.2. Key Takeaways from Analysts, Consultants, and Industry Leaders
  12. Chapter 12 Research Approach & Methodology
    1. 12.1. Report Description
    2. 12.2. Research Scope
    3. 12.3. Research Methodology
      1. 12.3.1. Secondary Research
      2. 12.3.2. Primary Research
      3. 12.3.3. Statistical Models
        1. 12.3.3.1. Company Share Analysis Model
        2. 12.3.3.2. Revenue Based Modeling
      4. 12.3.4. Research Limitations

      List of Figures

      Fig.1	Product Picture of Fabry Disease Treatment
      Fig.2	Global Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.3	Global Fabry Disease Treatment Market Absolute Revenue Opportunity, 2016 – 2026 (USD Million)
      Fig.4	Global Fabry Disease Treatment Market Incremental Revenue Opportunity, 2020 – 2026 (USD Million)
      Fig.5	Global Fabry Disease Treatment Market Share, by Drugs, 2019 & 2026 (USD Million)
      Fig.6	Global Agalsidase Beta Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.7	Global Migalastat Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.8	Global Pipeline Drugs Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.9	Global Fabry Disease Treatment Market Share, by Treatment, 2019 & 2026 (USD Million)
      Fig.10	Global Enzyme Replacement Therapy (ERT) Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.11	Global Chaperone Treatment Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.12	Global Substrate Reduction Therapy (SRT) Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.13	Global Others Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.14	Global Fabry Disease Treatment Market Share, by Route of Administration, 2019 & 2026 (USD Million)
      Fig.15	Global Oral Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.16	Global Intravenous Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.17	Global Fabry Disease Treatment Market Share, by Region, 2019 & 2026 (USD Million)
      Fig.18	North America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.19	U.S. Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.20	Canada Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.21	Europe Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.22	Germany Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.23	France Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.24	U.K. Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.25	Italy Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.26	Spain Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.27	Rest of Europe Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.28	Asia Pacific Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.29	China Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.30	Japan Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.31	India Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.32	South  Korea Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.33	South-East Asia Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.34	Rest of Asia Pacific Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.35	Latin America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.36	Brazil Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.37	Mexico Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.38	Rest of Latin America Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.39	The Middle-East and Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.40	GCC Countries Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.41	South Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.42	Rest of Middle-East Africa Fabry Disease Treatment Market, 2016 – 2026 (USD Million)
      Fig.43	Competitor Market Share – Revenue
      Fig.44	Sanofi S.A. Revenue and Growth Rate
      Fig.45	Sanofi S.A. Market Share
      Fig.46	Amicus Therapeutics Inc. Revenue and Growth Rate
      Fig.47	Amicus Therapeutics Inc. Market Share
      Fig.48	Avrobio Inc. Revenue and Growth Rate
      Fig.49	Avrobio Inc. Market Share
      Fig.50	Shire Plc. Revenue and Growth Rate
      Fig.51	Shire Plc. Market Share
      Fig.52	Idorsia Pharmaceuticals Ltd. Revenue and Growth Rate
      Fig.53	Idorsia Pharmaceuticals Ltd. Market Share
      Fig.54	Greenovation Biotech GmbH Revenue and Growth Rate
      Fig.55	Greenovation Biotech GmbH Market Share
      Fig.56	ISU Abxis Co Ltd. Revenue and Growth Rate
      Fig.57	ISU Abxis Co Ltd. Market Share
      Fig.58	Moderna Therapeutics Inc. Revenue and Growth Rate
      Fig.59	Moderna Therapeutics Inc. Market Share
      Fig.60	JCR Pharmaceuticals Co Ltd Revenue and Growth Rate
      Fig.61	JCR Pharmaceuticals Co Ltd Market Share
      Fig.62	Protalix Biotherapeutics Inc. Revenue and Growth Rate
      Fig.63	Protalix Biotherapeutics Inc. Market Share
      Fig.64	Market Dynamics
      Fig.65	Global Fabry Disease Treatment – Value Chain Analysis
      Fig.66	Key Mandates and Regulations
      Fig.67	Technology Roadmap and Timeline
      Fig.68	Market Attractiveness Analysis – By Drugs
      Fig.69	Market Attractiveness Analysis – By Treatment
      Fig.70	Market Attractiveness Analysis – By Route of Administration
      Fig.71	Market Attractiveness Analysis – By Region
      Fig.72	Fabry Disease Treatment Industrial Chain Analysis
      Fig.73	Market Channels
      Fig.74	Marketing Channel Development Trend
      Fig.75	Growth in World Gross Product, 2008-2018
      

      List of Tables

      Table 1	Global Fabry Disease Treatment Market, 2019 & 2026 (USD Million)
      Table 2	Global Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      Table 3	Global Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      Table 4	Global Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      Table 5	Global Fabry Disease Treatment Market, by Region, 2016 – 2026 (USD Million)
      Table 6	North America Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
      Table 7	North America Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      Table 8 North America Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      Table 9 North America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      Table 10 Europe Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
      Table 11 Europe Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      Table 12 Europe Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      Table 13 Europe Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      Table 14 Asia Pacific Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
      Table 15 Asia Pacific Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      Table 16 Asia Pacific Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      Table 17 Asia Pacific Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      Table 18 Latin America Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
      Table 19 Latin America Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      Table 20 Latin America Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      Table 21 Latin America Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      Table 22 The Middle-East and Africa Fabry Disease Treatment Market, by Country, 2016 – 2026 (USD Million)
      Table 23 The Middle-East and Africa Fabry Disease Treatment Market, by Drugs, 2016 – 2026 (USD Million)
      Table 24 The Middle-East and Africa Fabry Disease Treatment Market, by Treatment, 2016 – 2026 (USD Million)
      Table 25 The Middle-East and Africa Fabry Disease Treatment Market, by Route of Administration, 2016 – 2026 (USD Million)
      Table 26 Global Fabry Disease Treatment Market - Company Revenue Analysis, 2016 – 2019 (USD Million)
      Table 27 Global Fabry Disease Treatment Market - Company Revenue Share Analysis, 2016 – 2019 (%)
      Table 28 Acquisitions and Mergers
      Table 29 Market Drivers – Impact Analysis
      Table 30 Market Restraints
      Table 31 Market Opportunities
      Table 32 Major Buyers of Fabry Disease Treatment
      Table 33 Distributors/Traders of Fabry Disease Treatment by Region
      

Industry Major Market Players

  • ISU Abxis Co Ltd.
  • Greenovation Biotech GmbH
  • Amicus Therapeutics Inc.
  • Avrobio Inc.
  • Shire Plc.
  • Sanofi S.A.
  • Moderna Therapeutics Inc.
  • JCR Pharmaceuticals
  • Protalix Biotherapeutics Inc.
  • Idorsia Pharmaceuticals Ltd.

Safe and Secure SSL Encrypted

Choose License Type

Inquiry For Buying

COVID-19 Pandemic Impacts

Our Analysts and Consultants are working ceaselessly to congregate, identify, analyze, and portray the Actual Impacts of COVID-19 Global Pandemic in each of our published as well as ongoing research reports to Redefine and Revise Current and Future Market Trends, Growth Rates, And Market Size Projections across the Globe as well as in different Regions and individual Countries.

have a question

HAVE A QUESTION? Executive will help you find what you are looking for.


REQUEST CUSTOMIZATION

Still haven't found what you're looking for? Speak to our Custom Research Team

Learn More
Facts & Factors provides an array of marketing and business research solutions distinctly designed by our expertise for the clients.
Copyright © 2021 Facts & Factors. All Rights Reserved. Sitemap - Privacy Policy - Terms & Conditions